Companion diagnostics at the intersection of personalized medicine and healthcare delivery

Companion diagnostics at the intersection of personalized medicine and healthcare delivery.

Personalized Medicine in Oncology and Companion Diagnostics: Development and Challenges

The core of the whole concept of personalized medicine is to tailor medical practice, from prevention, diagnosis, treatment to prognosis, based on the underlying pathophysiological changes of the disease and the patient. More specifically, this approach may include new diagnostic tools to determine genetic alterations and expression, including the noncoding genetic elements, in order to more pr...

Infrastructure for Personalized Medicine at Partners HealthCare

Partners HealthCare Personalized Medicine (PPM) is a center within the Partners HealthCare system (founded by Massachusetts General Hospital and Brigham and Women's Hospital) whose mission is to utilize genetics and genomics to improve the care of patients in a cost effective manner. PPM consists of five interconnected components: (1) Laboratory for Molecular Medicine (LMM), a CLIA laboratory p...

Companion diagnostics and personalized medicine: A review of molecular diagnostic applications

Personalized medicine is the customization of treatment based on a patient’s hereditary or somatic genetics and holds the promise of revolutionizing healthcare. Companion diagnostics, many of which are molecular genetics assays, are critical tools in the implementation of personalized medicine. Information derived from these tests provides for customizing specific therapies based on the genetic...

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer

Companion diagnostics (CDx) have become a major tool in molecular pathology and assist in therapy decisions in an increasing number of various cancers. Particularly, the developments in lung cancer have been most impressing in the last decade and consequently lung cancer mutation testing and molecular profiling has become a major business of diagnostic laboratories. However, it has become diffi...